162 related articles for article (PubMed ID: 38320689)
21. Morphologic and Immunohistochemical Characterization of Spontaneous Lymphoma/Leukemia in NSG Mice.
Tillman H; Janke LJ; Funk A; Vogel P; Rehg JE
Vet Pathol; 2020 Jan; 57(1):160-171. PubMed ID: 31736441
[TBL] [Abstract][Full Text] [Related]
22. An Fc-engineered CD19 antibody eradicates MRD in patient-derived
Schewe DM; Alsadeq A; Sattler C; Lenk L; Vogiatzi F; Cario G; Vieth S; Valerius T; Rosskopf S; Meyersieck F; Alten J; Schrappe M; Gramatzki M; Peipp M; Kellner C
Blood; 2017 Sep; 130(13):1543-1552. PubMed ID: 28698205
[TBL] [Abstract][Full Text] [Related]
23. The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.
Richardson PG; Moreau P; Laubach JP; Gupta N; Hui AM; Anderson KC; San Miguel JF; Kumar S
Future Oncol; 2015; 11(8):1153-68. PubMed ID: 25832873
[TBL] [Abstract][Full Text] [Related]
24. Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor.
Gupta N; Hanley MJ; Xia C; Labotka R; Harvey RD; Venkatakrishnan K
Clin Pharmacokinet; 2019 Apr; 58(4):431-449. PubMed ID: 30117017
[TBL] [Abstract][Full Text] [Related]
25. The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor.
Hinsley S; Walker K; Sherratt D; Bailey L; Reed S; Flanagan L; McKee S; Brudenell Straw F; Dawkins B; Meads D; Auner HW; Kaiser MF; Cook M; Brown S; Cook G;
Trials; 2020 Oct; 21(1):826. PubMed ID: 33008427
[TBL] [Abstract][Full Text] [Related]
26. Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo.
Pierce MR; Robinson RM; Ibarra-Rivera TR; Pirrung MC; Dolloff NG; Bachmann AS
Leuk Res; 2020 Jan; 88():106271. PubMed ID: 31778912
[TBL] [Abstract][Full Text] [Related]
27. Variegated clonality and rapid emergence of new molecular lesions in xenografts of acute lymphoblastic leukemia are associated with drug resistance.
Nowak D; Liem NL; Mossner M; Klaumünzer M; Papa RA; Nowak V; Jann JC; Akagi T; Kawamata N; Okamoto R; Thoennissen NH; Kato M; Sanada M; Hofmann WK; Ogawa S; Marshall GM; Lock RB; Koeffler HP
Exp Hematol; 2015 Jan; 43(1):32-43.e1-35. PubMed ID: 25450514
[TBL] [Abstract][Full Text] [Related]
28. B cell acute lymphoblastic leukemia cells mediate RANK-RANKL-dependent bone destruction.
Rajakumar SA; Papp E; Lee KK; Grandal I; Merico D; Liu CC; Allo B; Zhang L; Grynpas MD; Minden MD; Hitzler JK; Guidos CJ; Danska JS
Sci Transl Med; 2020 Sep; 12(561):. PubMed ID: 32938796
[TBL] [Abstract][Full Text] [Related]
29. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
Park J; Park E; Jung CK; Kang SW; Kim BG; Jung Y; Kim TH; Lim JY; Lee SE; Min CK; Won KA
BMC Cancer; 2016 Mar; 16():247. PubMed ID: 27012957
[TBL] [Abstract][Full Text] [Related]
30. Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rgamma null mice generate a faster and more efficient disease compared to other NOD/scid-related strains.
Agliano A; Martin-Padura I; Mancuso P; Marighetti P; Rabascio C; Pruneri G; Shultz LD; Bertolini F
Int J Cancer; 2008 Nov; 123(9):2222-7. PubMed ID: 18688847
[TBL] [Abstract][Full Text] [Related]
31. Ixazomib for the treatment of multiple myeloma.
Gentile M; Offidani M; Vigna E; Corvatta L; Recchia AG; Morabito L; Morabito F; Gentili S
Expert Opin Investig Drugs; 2015; 24(9):1287-98. PubMed ID: 26138345
[TBL] [Abstract][Full Text] [Related]
32. High frequencies of leukemia stem cells in poor-outcome childhood precursor-B acute lymphoblastic leukemias.
Morisot S; Wayne AS; Bohana-Kashtan O; Kaplan IM; Gocke CD; Hildreth R; Stetler-Stevenson M; Walker RL; Davis S; Meltzer PS; Wheelan SJ; Brown P; Jones RJ; Shultz LD; Civin CI
Leukemia; 2010 Nov; 24(11):1859-66. PubMed ID: 20739953
[TBL] [Abstract][Full Text] [Related]
33. Ixazomib - the first oral proteasome inhibitor.
Xie J; Wan N; Liang Z; Zhang T; Jiang J
Leuk Lymphoma; 2019 Mar; 60(3):610-618. PubMed ID: 30614337
[TBL] [Abstract][Full Text] [Related]
34. Ixazomib in addition to chemotherapy for the treatment of acute lymphoblastic leukemia in older adults.
Amrein P; Ballen K; Stevenson K; Brunner A; Hobbs G; Hock H; McAfee S; Moran J; Bergeron M; Foster J; Bertoli C; McGreggor K; Macrea M; Burke M; Behnam T; Som T; Ramos A; Vartanian M; Lombardi Story J; Connolly C; Blonquist T; Neuberg D; Fathi A
Leuk Lymphoma; 2022 Jun; 63(6):1428-1435. PubMed ID: 35075985
[TBL] [Abstract][Full Text] [Related]
35. [Establishment of a Patient-Derived T-Cell Acute Lymphoblastic Leukemia Xenograft Model in Novel Immunodeficient NCG Mice].
Jiang PJ; Dai XB; Kong XT; Xu ZQ; Yu H; Pang J; Xia W; Yu JH; Zhu GR; Tian F; Zhu XJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):311-318. PubMed ID: 37096499
[TBL] [Abstract][Full Text] [Related]
36. Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma.
Assouline SE; Chang J; Cheson BD; Rifkin R; Hamburg S; Reyes R; Hui AM; Yu J; Gupta N; Di Bacco A; Shou Y; Martin P
Blood Cancer J; 2014 Oct; 4(10):e251. PubMed ID: 25325301
[TBL] [Abstract][Full Text] [Related]
37. Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients.
Gupta N; Huh Y; Hutmacher MM; Ottinger S; Hui AM; Venkatakrishnan K
Cancer Chemother Pharmacol; 2015 Sep; 76(3):507-16. PubMed ID: 26141494
[TBL] [Abstract][Full Text] [Related]
38. Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies.
Smith DC; Kalebic T; Infante JR; Siu LL; Sullivan D; Vlahovic G; Kauh JS; Gao F; Berger AJ; Tirrell S; Gupta N; Di Bacco A; Berg D; Liu G; Lin J; Hui AM; Thompson JA
Invest New Drugs; 2015 Jun; 33(3):652-63. PubMed ID: 25777468
[TBL] [Abstract][Full Text] [Related]
39. Ixazomib, an oral proteasome inhibitor, induces rapid mobilization of hematopoietic progenitor cells in mice.
Ghobadi A; Rettig MP; Holt MS; Ritchey JK; Kennerly K; Chendamarai E; Eissenberg L; DiPersio JF
Blood; 2018 Jun; 131(23):2594-2596. PubMed ID: 29695518
[No Abstract] [Full Text] [Related]
40. The nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse.
Lock RB; Liem N; Farnsworth ML; Milross CG; Xue C; Tajbakhsh M; Haber M; Norris MD; Marshall GM; Rice AM
Blood; 2002 Jun; 99(11):4100-8. PubMed ID: 12010813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
